Skip Navigation

European Heart Journal 2000 21(23):1913-1916; doi:10.1053/euhj.2000.2432
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Armstrong, P.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, P.W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Reperfusion synergism: will it be both sustained and safe?

P.W. Armstrong

University of Alberta, Edmonton, Alberta, U.S.A.

References

  1. Lancet. 1986;I:397–401
  2. Lancet. 1988;ii:349–360
  3. Collen D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation. 1996;93:857–865[Free Full Text]
  4. N Engl J Med. 1993;329:673–682[Abstract/Free Full Text]
  5. Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990;322:33–42[ISI][Medline]
  6. Topol EJ. Towards a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence. Circulation. 1998;97:211–218[Free Full Text]
  7. Ito H, Tomooka T, Sakai N. Lack of myocardial perfusion immediately after successful thrombolysis. Circulation. 1992;85:1699–1705[Abstract/Free Full Text]
  8. Coller BS. GP IIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730–755[ISI][Medline]
  9. Kong DF, Califf RM, Miller DP. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829–2835[Abstract/Free Full Text]
  10. Antman EM, Giugliano RP, Gibson CM. for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720–2732[Abstract/Free Full Text]
  11. Gold HK, Coller BS, Yasuda T. Rapid and sustained coronary artery recanalization with combined bolus injection of recombination tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670–677[Abstract/Free Full Text]
  12. Ohman EM, Califf RM, Topol EJ. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 1990;82:781–791[Abstract/Free Full Text]
  13. Circulation. 1997;95:846–854[Abstract/Free Full Text]
  14. J Am Coll Cardiol. 1998;32:2003–2010[Abstract/Free Full Text]
  15. Antman EM, Gibson CM, de Lemos JA. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Eur Heart J. 2000;21:1944–1953[Abstract/Free Full Text]
  16. de Lemos JA, Antman EM, Gibson M. Abciximab improves both epicardial flow and myocardial reperfusion in ST elevation myocardial infarction: Observations from the TIMI 14 trial. Circulation. 2000;101:239–243[Abstract/Free Full Text]
  17. Circulation. 2000;101:2788–2794[Abstract/Free Full Text]
  18. L'Allier PL, Lopez JF, Vrobel TR, Strony JS, Brener SJ. Favourable results with immediate coronary intervention after low dose t-PA and eptifibatide for acute MI: Results from the INTRO-AMI trial. Circulation. 1999;100:I-359
  19. Circulation. 1999;100:1016–1030[Free Full Text]
  20. Ross, AM, HART-II trial presented at 49th Annual Meeting of the American College of Cardiologists, Anaheim, California, March, 2000
  21. White HD, Aylward PE, Frey MJ. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 1997;96:2155–2161[Abstract/Free Full Text]
  22. Metz BK, White HD, Granger CB. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO IIb Trial. J Am Coll Cardiol. 1998;31:1493–1498[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
S. Savonitto, P.W. Armstrong, A.M. Lincoff, G. Jia, C.A. Sila, J. Booth, P. Terrosu, C. Cavallini, H.D. White, D. Ardissino, et al.
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial
Eur. Heart J., October 2, 2003; 24(20): 1807 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
E.P. McFadden
Fibrinolysis and stenting in acute myocardial infarction: newlyweds destined for a 'menage a trois'?
Eur. Heart J., July 1, 2001; 22(13): 1067 - 1069.
[PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Armstrong, P.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, P.W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?